The expanded efficacy data across both obstructive and non-obstructive HCM strengthens the case for aficamten as a potential standard-of-care for the full HCM spectrum, with the nHCM sNDA submission expected Q4 2026. Traders should watch for FDA acceptance and priority review designation. CYTK has a $10.8B market cap with 89% analyst buy ratings, consensus is already bullish, so a high-impact approval may already be partially priced in.
Drug in focus
CYTK drug pipeline →MYQORZO
▲ Bullish Named in this press release- Impact
- Phase
- Approved
- Time to market
- Already approved and commercializing in the U.S. (since December 2025) and Canada (October 2026). A label expansion decision from the FDA is expected November 14, 2026. A supplemental NDA for non-obstructive HCM is planned for submission in Q4 2026, with potential approval in 2027. EU submission is planned for early 2027.
- Next catalyst
- None dated
What to watchThe FDA decision on the MAPLE-HCM sNDA is due tomorrow, November 14, 2026. An approval would expand the label to include data showing aficamten's superiority over metoprolol, potentially strengthening the drug's positioning against standard-of-care beta blockers and BMS's Camzyos. A Complete Response Letter would be a negative surprise given the positive Phase 3 data. Separately, the supplemental NDA for non-obstructive HCM (ACACIA-HCM) is expected to be submitted in Q4 2026, which could be the next major catalyst.
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Aug 31 $70.91entry
- T+1 · 3mo ago +0.69%α +1.38% · $71.40
- T+5 · 2mo ago +6.26%α +6.40% · $75.35
- T+20 · 7w ago −7.43%α −7.06% · $65.64
- T+54 · todayOpen
- T+60 · in 7d Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Cytokinetics presented positive additional Phase 3 results at ESC 2026 showing aficamten (MYQORZO) improves cardiac structure and diastolic function in non-obstructive HCM and outperforms metoprolol across pre-trial treatment groups in obstructive HCM. The company plans to submit a supplemental NDA for the nHCM indication in Q4 2026, expanding the drug's potential addressable market beyond the currently approved oHCM population.
Key Facts
- Additional ACACIA-HCM results showed aficamten significantly improved diastolic function (peak E velocity, septal e' velocity) and reduced left ventricular wall thickness (-0.2 cm, p<0.001) in nHCM at up to 72 weeks.
- MAPLE-HCM post-hoc analysis showed aficamten improved pVO2 vs metoprolol irrespective of prior beta-blocker use (no beta blockers: +3.1 mL/kg/min, p<0.001; on beta blockers: +1.9 mL/kg/min, p<0.001).
- Cytokinetics plans to submit a Supplemental New Drug Application for aficamten in non-obstructive HCM in Q4 2026.
Financial Impact
Expansion of aficamten's addressable market to ~50% of HCM patients (nHCM) who currently have no approved therapies; sNDA submission Q4 2026
Risk Factors
- FDA could issue a Complete Response Letter or require additional trials for nHCM, delaying or denying approval.
- Competition from existing therapies (mavacamten/camzyos) and other emerging HCM drugs could limit market share.
- Aficamten's boxed warning for heart failure risk and REMS program may limit uptake in broader nHCM population.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3352934 |
Track record
46 reports on CYTK
7 of 10 bullish or bearish reports moved the stock their way by T+20. Best: +8.59% at T+20 after the Sep 15, 2026 report. 9 of 10 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $53.76 Now $56.13 +4.41% settles Dec 15
- Nov 12, 20264d ago Insider Cluster Neutral 3/10 Entry $56.13 Now $56.13 +0.00% settles Dec 14
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $56.18 Now $56.13 −0.09% settles Dec 9
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $56.18 Now $56.13 −0.09% settles Dec 9
- Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $55.14 Now $56.13 +1.80% settles Dec 8
- Nov 9, 20267d ago Press Release Neutral 4/10 Entry $55.14 Now $56.13 +1.80% settles Dec 8
- Nov 4, 202612d ago 8-K Bullish 6/10 No price data
- Nov 4, 202612d ago Press Release Neutral 5/10 Entry $55.55 Now $56.13 +1.04% settles Dec 4
- Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $63.60 Now $56.13 −11.75% settles Dec 3
- Nov 2, 202614d ago Press Release Neutral 3/10 Entry $62.03 Now $56.13 −9.51% settles Dec 1
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers